Samsung Bioepis Co., Ltd. today announced that the company has begun direct commercialization of BYOOVIZ ®, a biosimilar to Lucentis 1 (ranibizumab), in Europe. Samsung Bioepis has been working to ...
Samsung Bioepis completes full transfer of commercial rights from Biogen back to Samsung Bioepis for BYOOVIZ BYOOVIZ becomes the fourth biosimilar directly commercialized by Samsung Bioepis ...
GlobalData on MSN
Revamping best-selling drugs to combat patent cliff has limits
Updated versions of best-selling drugs may mitigate some of the impact of patent cliff losses, but strategy is key in a ...
A single cup of chopped pineapple delivers a generous dose of vitamin C, covering well over three quarters of the daily ...
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that the U.S.
The Pooled Cohort Equations (PCE) cardiovascular risk score stratifies risk for multiple ocular diseases, according to a ...
The top read ophthalmology articles of 2025 focused on a variety of topics within the field, including links between ...
FDA approvals in 2025 introduced novel therapies and devices across ophthalmic subspecialties, emphasizing sustained efficacy ...
A popular diabetes and weight-loss drug called semaglutide—sold under brand names like Ozempic and Wegovy—may come with an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback